Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6469682

COCCOc1ccc2nc(Nc3nc(O)c4cc(N)cc(C)c4n3)nc(C)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.39
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 7/20 0.37
ALDH1A1 P00352 6/20 0.37
LMNA P02545 2/20 0.37
USP2 O75604 2/20 0.37
RAB9A P51151 1/20 0.37
AURKA O14965 1/20 0.36
ERBB2 P04626 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
HTT P42858 2/20 0.36
PSMD14 O00487 1/20 0.36
APAF1 O14727 1/20 0.36
MITF O75030 1/20 0.36
HPGD P15428 1/20 0.36
PTK2B Q14289 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6470554 0.90 KDM4E (0.46) KDM4EMEN1KMT2AMAPTALDH1A1
Trifluoroacetic Acid SCHEMBL6466210 0.89 SRC (0.39) KDM4EMEN1KMT2AGAAMAPT
Trifluoroacetic Acid SCHEMBL6470133 0.87 KMT2A (0.35) KDM4EMEN1KMT2AGAAMAPT
SCHEMBL6469684 0.87 KDM4E (0.38) KDM4EMEN1KMT2AGAAMAPT
Trifluoroacetic Acid SCHEMBL6470467 0.84 ADORA2A (0.40) KDM4EMEN1KMT2AGAAMAPT
Trifluoroacetic Acid SCHEMBL6466263 0.83 MAPT (0.40) KDM4EMEN1KMT2AGAAMAPT
Trifluoroacetic Acid SCHEMBL6467460 0.82 KDM4E (0.45) KDM4EMEN1KMT2AMAPTALDH1A1
Trifluoroacetic Acid SCHEMBL6469598 0.82 MAPT (0.41) KDM4EMEN1KMT2AMAPTALDH1A1
Trifluoroacetic Acid SCHEMBL6469262 0.80 TDP2 (0.48) KDM4EMEN1KMT2AMAPTALDH1A1
Trifluoroacetic Acid SCHEMBL6465684 0.79 KMT2A (0.33) KDM4EMEN1KMT2AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB KDM4E 3225/4885MEN1 4218/4885KMT2A 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.